A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study

Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO

“…Both rates compare favorably with other randomized studies in elderly patients as well as the standard CHOP chemotherapy regimen. 24,27,29,[57][58][59] The data from this trial confirm the finding from The International Non-Hodgkin's Lymphoma Prognostic Factors Project (IPI) that patients older than 60 years had CR rates that were similar to those observed in younger patients. 12 Patients in the mitoxantrone arm had significantly better overall survival and trend for improved cause-specific survival, reflecting durable remissions after chemotherapy in this group (Figures 2-4).…”

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach

“…49 Thereafter, secondand third-generation regimens were developed that appeared to cure 55% to 65% of patients; however, despite these encouraging results, randomized trials of these regimens versus CHOP showed no survival differences (Table 3). [50][51][52] Results of these studies secured the role of CHOP as the standard of care in DLBCL, so much so that it was nearly a decade until additional trials sought to improve on the success of CHOP. 53 The striking differences between the encouraging phase 2 trials and subsequent phase 3 studies may reflect the inclusion of better risk patients in early trials and more representative patients in the later randomized studies.…”

‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’

“…The incidence of NHL continues to rise and currently NHL ranks the fifth in cancer mortality. Combination chemotherapy is the standard treatment option for aggressive NHL (Fisher et al, 1993), although only 40% of patients with aggressive NHL are cured and the majority of patients become refractory to such treatments. Newer biological therapies have emerged during the last years and offered alternative options to treat unresponsive malignant disease.…”